Corral JE, Mera R, Dye CW, Morgan DR. Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention. World J Gastrointest Oncol 2017; 9(4): 184-193 [PMID: 28451066 DOI: 10.4251/wjgo.v9.i4.184]
Corresponding Author of This Article
Douglas R Morgan, MD, MPH, Director for Latin America Sites, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, 1030C MRB IV, 2215 Garland Avenue, Nashville, TN 37232, United States. douglas.morgan@vanderbilt.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2017; 9(4): 184-193 Published online Apr 15, 2017. doi: 10.4251/wjgo.v9.i4.184
Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention
Juan E Corral, Robertino Mera, Corey W Dye, Douglas R Morgan
Juan E Corral, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, United States
Robertino Mera, Douglas R Morgan, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, Nashville, TN 37232, United States
Corey W Dye, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, United States
Author contributions: Corral JE and Morgan DR designed the research; Corral JE and Dye CW performed the systematic review; Corral JE, Mera R and Morgan DR performed statistical analysis; Corral JE and Morgan DR wrote the manuscript; Mera R and Morgan DR critically reviewed the manuscript.
Supported by In part grants from the United States National Institutes of Health, Nos. CA1255884, CA167773, CA028842 (to Morgan DR).
Conflict-of-interest statement: The authors declare no conflict of interests.
Data sharing statement: Technical appendix, statistical code and dataset available from the corresponding author at (douglas.morgan@vanderbilt.edu).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Douglas R Morgan, MD, MPH, Director for Latin America Sites, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, 1030C MRB IV, 2215 Garland Avenue, Nashville, TN 37232, United States. douglas.morgan@vanderbilt.edu
Telephone: +1-615-3229374
Received: October 11, 2016 Peer-review started: October 13, 2016 First decision: November 14, 2016 Revised: December 14, 2016 Accepted: January 2, 2017 Article in press: January 3, 2017 Published online: April 15, 2017 Processing time: 181 Days and 8.5 Hours
Core Tip
Core tip: Latin America has a high burden of gastric cancer mortality, with significant geographical variability, which offers the opportunity for prevention trials and interventions. Recent trials and meta-analysis show that Helicobacter pylori (H. pylori) eradication reduces the risk of gastric adenocarcinoma. H. pylori reinfection rates in Latin America are similar to those seen in Asian trials. Recurrent cases occur mostly within the first year suggesting treatment failure (re-growth), not reinfection. These findings were not significantly modified by diagnostic modality, the antibiotics selected, retreatment, or the time check for eradication success. Eradication programs are a potentially attractive strategy for gastric cancer prevention in Latin America.
